IP Library › Granted Patent US 12,281,123
Granted Patent B2
US 12,281,123 · App. 18/295,009 · Granted Apr 22, 2025

Benzoxazinone compounds as KLK5/7 dual inhibitors

Inventors: Andreas Betz (Palo Alto, CA); Robert Zamboni (Palo Alto, CA)
Assignee: MOLECULAR SKIN THERAPEUTICS, INC.
C07D498/04A61K9/0014A61P17/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,123
App. No.
18/295,009
Granted
Apr 22, 2025
Kind
B2
Abstract

The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): wherein R is as described herein.

Claims (14)

1. A method of treating Netherton Syndrome in a subject in need thereof, comprising administering to said subject a pharmaceutical composition comprising:

a) an effective amount of a compound having formula (I):

or a pharmaceutically acceptable complex thereof; and

b) a pharmaceutically acceptable carrier,

wherein R is H or a member selected from the group consisting of —R 1 and —C(O)R 1a , wherein R 1 is C 1-12 alkyl, and R 1a is H or C 1-12 alkyl.

2. The method of claim 1 , wherein said compound has formula (Ia):

or a pharmaceutically acceptable complex thereof.

3. The method of claim 1 , wherein said compound has a formula selected from the group consisting of:

or a pharmaceutically acceptable complex thereof.

4. The method of claim 1 , wherein said pharmaceutical composition is administered topically.

5. The method of claim 1 , wherein said compound has a formula:

or a pharmaceutically acceptable complex thereof.

6. The method of claim 1 , wherein said compound has a formula:

or a pharmaceutically acceptable complex thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.
Reel/Frame 070551/0095 →
SECURITY INTEREST Recorded Jan 19, 2024
From: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; THERAS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066355/0126 →
SECURITY INTEREST Recorded Jan 17, 2024
From: CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066342/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2023
From: BETZ, ANDREAS; ZAMBONI, ROBERT
To: MOLECULAR SKIN THERAPEUTICS, INC.
Reel/Frame 065118/0452 →
Continuity (3)
Continuation 17037910 · Sep 30, 2020
Provisional Application 62909006 · Oct 1, 2019
Related Publication 20240067658A1 · Feb 29, 2024
References Cited (20)
US 4980287A · Kokubo et al. · 1990 [cited by applicant]
US 11643420B2 · Betz et al. · 2023 [cited by applicant]
US 20030187256A1 · Berrmany et al. · 2003 [cited by applicant]
US 20170002021A1 · Wagberg et al. · 2017 [cited by applicant]
WO 9308254A1 · 1993 [cited by applicant]
WO 9809790A1 · 1998 [cited by applicant]
WO 2004108139A2 · 2004 [cited by applicant]
WO 2004108139A3 · 2004 [cited by applicant]
WO 2015112081A1 · 2015 [cited by applicant]
WO WO2015112081 · 2015 [cited by examiner]
Kalinska et al (Biochime 122:270-282, 2016) (Year: 2016). [cited by examiner]
Di Paolo et al (Critical Reviews in Clinical Laboratory Sciences 58:Jan. 16, 2021) (Year: 2021). [cited by examiner]
Novartis Pharma AG (Clinical Trial Results Website, Feb. 13, 2015, 13 Pages) (Year: 2015). [cited by examiner]
International Search Report mailed Jan. 22, 2021 corresponding to PCT/US2020/053369 filed Sep. 30, 2020; 14 pages. [cited by applicant]
Extended European Search Report mailed Aug. 30, 2023 corresponding to EP 20872712.3 filed Sep. 30, 2020; 4 pages [no additional references cited]. [cited by applicant]
Di Paolo, Caitlin et al., “The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets,” [cited by applicant]
Kalinska, Magdalena et al., “Kallikreins—the melting pot of activity and function,” [cited by applicant]
Kantyka, Tomasz et al., “Inhibition of kallikrien-related peptidases by the serine protease inhibitor of Kazal-type 6,” [cited by applicant]
Novartis Pharma AG (Clinical Trial Results Website, Feb. 13, 2015); 13 pages. [cited by applicant]
PUBCHEM 2993515 deposited Jul. 29, 2005; pp. 1-6. [cited by applicant]